OptimizeRx CorporationOPRXNASDAQ
Loading
EV/EBITDA Over TimeContracting
Percentile Rank71
5Y CAGR-54.2%
Studio
Year-over-Year Change

Enterprise value to EBITDA ratio

5Y CAGR
-54.2%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
0x
Contraction
Streak
3 yr
Consecutive growthContracting
PeriodValueYoY Change
202514.05+215.0%
2024-12.22+2.8%
2023-12.58+57.8%
2022-29.82-107.0%
2021423.69-39.4%
2020698.68+985.0%
2019-78.95-184.7%
201893.17+509.0%
2017-22.78-74.4%
2016-13.06-